It is the future direction, a tool for delivery of better quality health to meet rising demand. There is no stopping it, no turning back the clock, should anybody but want to. Whether it's an opportunity or a threat – for it is both depending on where you sit – it is changing the way health care is delivered and accessed, and where it can be delivered, for good.
Digital And Connected Care Are Pushing On An Open Door – But Is Medtech Ready?
Digital health care will one day simply be "health care" in the same way that genomic medicine will simply become "medicine." But between then and now, there is much distance to cover – a lot of it in the minds of stakeholders who, maybe reluctantly, see it as a risky strategy. But the emerging consensus is that it represents opportunity.
More from Innovation
More from In Vivo
• By
Antag CEO Joerg Moeller talked to In Vivo about the young company’s gilded roots, and how its GIP receptor antagonist asset will differentiate in the crowded obesity market.
• By
Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.
• By
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.